26 3

The Science.

Click here to view more

Unlocking epigenetics.

We believe that epigenetics is the most exciting field in disease detection and management today.

Genetics—the study of the sequence of molecular “letters” that make up the DNA double helix itself—has had an enormous impact on the practice of medicine, revolutionizing the way doctors identify people with inherited conditions, diagnose cancer, and, increasingly, design personalized treatment plans. However, there’s more to chromosomes than just the DNA sequence; at Volition we focus on chromosomes’ second epigenetic code, which contains a wealth of additional information about the health of the body’s cells.

You can think of the DNA sequence of each cell as being like the text of an instruction manual, and epigenetics as being like the formatting.

Some parts of the manual are bolded, highlighted, or underlined, telling the cell to emphasize those sections, while others are struck out, telling the cell to ignore those genes at this time.

The cells of most organs in the body are continuously replaced by new ones, and the old cells release their nucleosomes into the bloodstream as they die. Our patented Nucleosomics technology isolates circulating nucleosomes from the blood for quantification and analysis.

The Nu.Q® family of tests (short for nucleosome quantification) will offer a convenient and cost effective new approach to the detection and diagnosis of diverse diseases from a simple blood test.

Highlighting abnormalities.

Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer and other diseases.

Epigenetic changes can be detected before the diseased cells themselves become abnormal enough to show up in traditional biopsies, and oftentimes before the first symptoms are felt.

We aim to replace unpleasant, invasive, and often expensive screening and diagnostic tests such as colonoscopies and biopsies with Nu.Q® blood tests, helping to save lives and to reduce overall health care costs.

  • Population Screening

    Our technology and tests could potentially play a game-changing role in early detection of disease in asymptomatic people via routine, population-wide screening.

    We believe that simple, cost effective, and accurate tests are the “holy grail” of an effective screening program.

  • Risk Stratification and Diagnostic Aid

    As well as being highly informative in their own right, Nu.Q® tests have the potential to improve the sensitivity and specificity of other clinical tests. Our tests could also reduce the number of people needing invasive biopsies and other diagnostic procedures, which can be expensive and harmful.

  • Disease and Treatment Monitoring

    Nu.Q® tests may act as an early warning system by monitoring treatment response, disease progression and remission.